At 12.9% CAGR, the Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market is projected to be worth US$ 2,821.07 million by 2033, says Business Market Insights

According to Business Market Insights research, the Asia Pacific manufacturing execution system in life sciences market was valued at US$ 834.86 million in 2023 and is expected to reach US$ 2,821.07 million by 2033, registering a CAGR of 12.9% from 2023 to 2033. Need for compliances with regulatory framework and requirement of accurate real-time data in production management process are the critical factors attributed to the Asia Pacific manufacturing execution system in life sciences market expansion. 

Manufacturing execution systems (MES) are solutions that aid pharmaceutical and medical device manufacturers to easily comply with such regulations while capturing details on each step of the manufacturing process. The FDA requires every medical device manufacturer to maintain Design History File (DHF) and Device History Records (DHR) to ensure that DHRs for each batch, lot, or unit can further help demonstrate that the device is manufactured as per the Device Master Record (DMR) and the requirements of this devices. DHR includes all the details pertinent to manufacturing a medical device, while DHF demonstrates the history of how the product was designed. The data was traditionally recorded on paper, which consisted of production travelers and other documentation. However, these paper-oriented processes expose companies to unnecessary risks, including in-process deviations and non-conformances, which can lead to product quality issues in the field. Modern MES have built-in features that enforce production processes and capture information associated with production records. In addition, pharmaceutical companies are also adopting Electronic Batch Manufacturing Record (eBMR) in place of paper-based Batch Manufacturing Record (BMR). eBMR can help them comply with global regulatory norms, quality processes, and ALCOA+ norms. ALCOA+ is a set of principles that ensures data integrity in the life sciences sector and is crucial for complying with Good Manufacturing Practices (GMP). Such integrations of features into the MES that ensure compliance with the regulatory framework boost the demand for MES in the pharmaceutical & medical device manufacturing industry.

On the contrary, high cost and lack of flexibility hampers the Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market .  

Based on offering, the Asia Pacific manufacturing execution system in life sciences market is segmented into software and services. The services segment held 71.0% share of Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market  in 2023, amassing US$ 592.76 million. It is projected to garner US$ 2,051.82 million by 2033 to expand at 13.2% CAGR during 2023–2033. 

Based on deployment, the Asia Pacific manufacturing execution system in life sciences market is segmented into on-premises and cloud. The on-premises segment held 52.0% share of Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market  in 2023, amassing US$ 434.13 million. It is projected to garner US$ 1,077.53 million by 2033 to expand at 9.5% CAGR during 2023–2033.

Based on organization size, the Asia Pacific manufacturing execution system in life sciences market is segmented into SMEs and large enterprises. The large enterprises segment held 77.3% share of Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 645.57 million. It is projected to garner US$ 2,139.74 million by 2033 to expand at 12.7% CAGR during 2023–2033.

Based on application, the Asia Pacific manufacturing execution system in life sciences market is segmented into pharmaceutical, biotechnology, and medical devices. The medical devices segment held 44.4% share of Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market  in 2023, amassing US$ 371.02 million. It is projected to garner US$ 1,270.86 million by 2033 to expand at 13.1% CAGR during 2023–2033.

Based on country, the Asia Pacific manufacturing execution system in life sciences market has been categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.9% share of Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market  in 2023. It was assessed at US$ 258.31 million in 2023 and is likely to hit US$ 915.16 million by 2033, exhibiting a CAGR of 13.5% during the forecast period.      

Key players dominating the Asia Pacific manufacturing execution system in life sciences market are Atachi Systems; ATS Global B.V.; Emerson Electric Co; LZ Lifescience Limited; Rockwell Automation Inc; Schneider Electric SE; and Siemens AG, among others.   

• Jan 2023, Autolomous LTD—a developer of critical manufacturing management systems for Cell and Gene Therapies (CGT)—announced a license agreement with US-based Center for Breakthrough Medicines (CBM), a cell and gene therapy contract development, manufacturing, and testing organization (CDMO). The agreement allowed Autolomous to design, configure and integrate solutions for CBM utilizing the AutoloMATE platform. It is a business-critical robust digital system, providing CBM with seamless digital connectivity in the manufacturing operations across all critical elements (e.g., facility systems, technologies) for the end-to-end cell and gene therapy (CGT) value chain.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com